Conjugated Polymeric-Based Prodrug to enhance steroidal delivery into cartilages (360G-Wellcome-109455_Z_15_Z)
Osteoarthritis (OA) is the key disease focus of the project, mainly through an improvement of the currently available drugs uptake. Additionally, a more selective distribution of the drug in the cartilage will reduce the required dose; both factors contributing to a reduction of the side effects associated with the drugs. The prevalence rate for OA is 11.3% or approximately 85 million people globally. It is expected to increase from 85 million in 2009 to 122 million in 2017. The main reason for this is the high incidence rate in the elderly population and the aging population trend. In addition, a rapid increase in the obese population will also contribute to an increase of the incidence of OA.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Amount Awarded | 73028 |
| Applicant Surname | Prokopovich |
| Approval Committee | Pathfinders Assessment Group |
| Award Date | 2015-08-25T00:00:00+00:00 |
| Financial Year | 2014/15 |
| Grant Programme: Title | Pathfinder Award |
| Internal ID | 109455/Z/15/Z |
| Lead Applicant | Dr Polina Prokopovich |
| Partnership Value | 73028 |
| Planned Dates: End Date | 2018-03-31T00:00:00+00:00 |
| Planned Dates: Start Date | 2016-01-01T00:00:00+00:00 |
| Recipient Org: Country | United Kingdom |
| Region | Wales |